nearly significantp=0.07
The pooled analysis showed that the sequential combined treatment was associated with a 36% reduction of the risk of relapse, a significantly better DFS (HR, 0.63; 95% confidence interval [CI], 0.41 to 0.99; p=0.04), cancer specific survival (HR, 0.55; 95% CI, 0.35 to 0.88; p=0.01) and a nearly significant improvement of OS (HR, 0.69; 95% CI, 0.46 to 1.03; p=0.07).